flubendazole has been researched along with Angiogenesis, Pathologic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Acharya, G; Elahy, M; Khachigian, LM; Li, Y; Xin, H | 1 |
1 other study(ies) available for flubendazole and Angiogenesis, Pathologic
| Article | Year |
|---|---|
The anthelmintic flubendazole blocks human melanoma growth and metastasis and suppresses programmed cell death protein-1 and myeloid-derived suppressor cell accumulation.
Topics: Animals; Antinematodal Agents; Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Female; Humans; Lung Neoplasms; Mebendazole; Melanoma; Mice; Mice, SCID; Myeloid-Derived Suppressor Cells; Neoplasm Metastasis; Neovascularization, Pathologic; Programmed Cell Death 1 Receptor; Random Allocation; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2019 |